Signoretti Lab Publications

Original Articles

1. Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Gerburg MW, Bell EL, Shim HS, Lamia KA, Rameh LE, Bellinger G, Sasaki AT, Asars JM, Yuan X, Bullock A, DeNicola GM, Song J. Brown V, Signoretti S, and Cantley LC. Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53 Null Tumors. Cell. In Press.
2. Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S. The role of aberrant VHL/HIF/VEGF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. In Press.
3. Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez- Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL & Pandolfi PP. Lrf/Pokemon suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet. In Press
4. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. Identification of new molecular genetics determinants, mechanisms and therapies for prostate cancer through Co- Clinical screenings. Nat Genet. In Press.
5. Comprehensive Molecular Characterization Of Clear Cell Renal Cell Carcinoma. The Cancer Genome Atlas Research Network. Nature. 2013 Jul 4;499(7456):43-9.
6. Pignon JC, Grisanzio C, Geng Y, Song J, Shivdasani RA, Signoretti S. p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia. Proc Natl Acad Sci (U S A). 2013;110(20):8105-10.
7. Emerling BM, Benes CH, Poulogiannis G, Bell EL, Courtney K, Lui H, Choo-Wing R, Bellinger R, Brown V, Signoretti S, Soltoff SP, and Cantley LC. Identification of CDCP1 as a HIF-2α target gene that is associated with survival in clear cell renal cell carcinoma patients. Proc Natl Acad Sci (U S A). 2013;110:3483-8.
8. Wang X, Zhang L, O’Neill A, Bahamon B, Alsop DC, Mier JW, Goldberg SN, Signoretti S, Michael B. Atkins MB, Wood CG, Bhatt RS. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer. 2013;108:319-26.
9. Schutz FA, Pomerantz MM, Gray KP, Atkins MB, Rosenberg JE, Hirsch MS, McDermott DF, Lee MG, Signoretti S, Kantoff PW, Freedman ML, and Choueiri TK. Polymorphisms and Risk of Recurrence in Renal Cell Cancer. Lancet Oncol. 2013;14:81-7.
10. Jia S, Gao X, Lee SH, Maira SM,Wu X, Stack E, Signoretti S, Loda M, Zhao JJ, Roberts TM. Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. Cancer Discovery. 2013;3:44-51.
11. Choi YJ, Li X, Hydbring P, Stefano J, Sanda T, Christie AL, Signoretti S, Look AT, Kung AL, von Boehmer H, and Sicinski P. The Requirement for Cyclin D Function in Tumor Maintenance. Cancer Cell. 2012;22:438-51.
12. Kuznetsov HS, Marsh T, Markens BA, Castaño Z, Greene-Colozzi A, Hay S, Brown VE, Richardson AL, Signoretti S, Battinelli EM, McAllister SS. Identification of Luminal Breast Cancers that Establish a Tumor Supportive Macroenvironment Defined by Pro-Angiogenic Platelets and Bone Marrow Derived Cells. Cancer Discovery. 2012;2:1150-65
13. Choueiri TK, Cheng SC, Qu AQ, Pastorek J, Pena C, Atkins MB, and Signoretti S. Carbonic Anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the Treatment Approaches in Renal Cancer Global Evaluation Trial (TARGET). Urol Oncol. 2012 Nov 7. [Epub ahead of print].
14. Choueiri TK, Cheville J, Palescandolo E, Kantoff P, Atkins MB, McKenney JK, Brown V, Lampron M, Zhou M, Hirsch MS and Signoretti S. BRAF mutations in metanephric adenoma of the kidney. Eur Urol. 2012 Jun 9. [Epub ahead of print].
15. Tron AE, Arai T, Duda DM, Kuwabara H, Olszewski J, Fujiwara Y, Bahamon BN, Signoretti S, Schulman BA, DeCaprioJA. The Glomuvenous Malformation Protein Glomulin Binds Rbx1 and regulates Cullin RING Ligase-Meditated Turnover of Fbw7. Mol Cell. 2012;46(1):67-78.
16. Wang X, Zhang L, Goldberg SN, Bhasin M, Brown V, Alsop DC, Signoretti S, Meir JW, Atkins MB, Bhatt RS. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. J Trans Med. 2011;9(1):220.
17. Yang W, Ahmed M, Tasawwar B, Levchenko T, Sawant RR, Collins M, Signoretti S, Torchilin V, Goldberg SN. Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model. Int J Hyperthermia. 2011;27(6):527-38
18. Bass AJ, Lawrence MS, Brace LE, Ramos AH, Drier Y, Cibulskis K, Sougnez, C, Voet D, Saksena G, Sivachenko A, Jing R, Parkin M, T, Verhaak RG, Stransky N, Boutin AT, Barretina J, Solit DB, Vakiani E, Shao W, Mishana Y, Warmuth M, JimenzJ, Chiang DY, Signoretti S, Kaelin WG, Spardy N, Hahn WC, Hoshida Y, Ogino S, Despinho RA, Chin L, Garraway LA, Fuchs CS, Baselga J, TabernoJ, Gabriel S, Lander ES, Getz G, Myerson M. Genomic sequencing of colorectal adencarcinomas identifies a recurrent VTI1A-TCF7L2 fusion. Nat Genet. 2011 Sep 4
19. Lin W, Coa J, Beshiri ML, Fujiwara Y, Francis J, Cherniack AD, Geisen C, Blair LP, Zou MR, Shen X, Kawamori D, Liu Z, Grisanzio C, Watanabe H, Minamishima YA, Zhang Q, Klukarni RN, Signoretti S, Rodig SJ, Bronson RT, Orkin SH, Tuck DP, Benevolenskaya EV, Meyerson M, Kaelin WG, and Yan Q. Loss of the RBP2 histone demethylase suppresses tumorigensis in mice lacking Rb1 or Men1. Proc Natl Acad Sci (USA).
20. Shen C, Beroukhim R, Schumacher S, Zhou J, Chang M, Signoretti S, and Kaelin WG. Genetic and Functional Studies Implicate H1F1alpha as 14q Kidney Cancer Suppressor Gene. Cancer Discovery.
21. Grisanzio C, Seeley A, Chang M, Collins M, Di Napoli A, Cheng SC, Percey A, Beroukim R, Signoretti S. Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumors in patients. J. Pathol. 2011 May 2.
22. Zhang L, Bhasin M, Schor-Bardach R, Wang X, Collins MP, Panka D, Putheti P, Signoretti S, Alsop DC, Libermann T, Atkins MB, Mier JW, Goldberg NS, Bhatt RS. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression. PLoS ONE, 2011;6(4):e19144.
23. Lee SH, Jia S, Zhu Y, Utermark T, Signoretti S, Loda M, Schaffhausen B, Roberts TM. Transgenic expression of polyoma virus middle T antigen in the mouse prostate gives rise to carcinoma. J. Virol. 2011;85(11):5581-92.
24. Flavin R, Finn SP, Choueiri TK, Ingoldsby H, Ring M, Barrett C, Rogers M, Smyth P, O'Regan E, Gaffney E, O'Leary JJ, Loda M, Signoretti S, Sheils O. RET protein expression in papillary renal cell carimona. Urol Oncol. 2011 Mar 9.
25. Bernardi R, Papa A, Egia A, Coltella N, Teruya-Feldstein J, Signoretti S, and Pandolfi PP. Pml represses tumor progression through inhibition of mTOR. EMBO Mol Med. 2011;3(5):249-57.
26. Ding Z, Wu C, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott AL,Signoretti, S, El-Bardeesy NM, Wang YA, Hill D, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L and DePinho RA. SMAD4-dependent barrier constrains prostate growth and metastatic progression. Nature. 2011. 2011;470(7333):269-73.
27. Gan B, Lim C, Chu G, Hua S, Ding Z, Collins M, Hu J, Jiang S, Fletcher-Sananikone E, Zhuang L, Chang M, Zheng H, Wang YA, Kwiatkowski DJ, Kaeline WG, Signoretti S and DePinho RA. FoxOs enforce a progression checkpoint to constrain mTORC1- activated renal tumorigenesis. Cancer Cell. 2012;18(5):472-84.
28. Moslehi J, Minamishima YA, Padera RF, Signoretti S, Liao R and Kaelin WG. Loss of PHD Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy. 2010 Sep7;122(10)1004-16.
29. Bhatt R, Wang X, Zhang L, Collins M, Signoretti S, Alsop D, Goldberg SN, Atkins MB, Mier JW. Renal cancer resistanceto antiangiogenic therapy is delayed by restoration of angiostatic signaling. Mol Cancer Ther. 2010:9(10):2793-802.
30. Genega EM, Ghebremichael M, Najarian R, Fu Y, Wang Y, Argani P, Grizanzio C, Signoretti S. CAIX Expression in Renal Neoplasms: correlation with Tumor Type and Grade. Am J Clin Pathol. 2010;134(6):873-9.
31. Yang W, Ahmed M, Elian M, Hady ES, Levchenko TS, Sawant RR, Signoretti S, Collins M, Torchilin VP, Goldberg SN. Do Liposomal Apoptotic Enhancers Increase Tumor Coagulation and End-Point Survival in Percutaneous Radiofrequency Ablation of Tumors in Rat Tumor Model? Radiology 2012 Sep 21.
32. Solazzo SA, Ahmed M, Schor-Bardach R, Yang W, Girnun GD, Rahmanuddin S, Levchenko T, Signoretti S, Spitz DR, Torchilin V, Goldberg SN. Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. Radiology. 2010 Apr; 255(1):62-74.
33. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW. The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared to Rapamycin in Renal Cell Carcinoma. Clin Cancer Res. 2010;16(14):3628-38. Link
34. Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, and Roberts TM. A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci (U S A). 2010;107(24):11002-7. Link
35. Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S. Carbonic anhydrase IX (CAIX) and pathologic features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving VEGF-targeted therapy. BJU Int. 2010;106(6):772-8.Link
36. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, McHenry K, Pinchback R, Ligon AH, Cho J, Haery L, Greulich H, Reich M, Winckler W, Weir BA, Tanaka K, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Yecies D, SignorettiS, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Baselga J, Tsao M, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Lander ES, Getz G, Golub TR, Sellers WR, Meyerson M. The landscape of copy number alterations across multiple human cancers. Nature. 2010;463:899-905. Link
37. Wiklund F, Tretli S, Choueiri TK, Signoretti S, Fall K, Adami HO. Risk of bilateral renal cell cancer. J Clin Oncol. 2009 Aug 10; 27(23):3737-41.
38. Sabbisetti V, Di Napoli A, Seeley A, Amato AM, O'Regan E, Ghebremichael M, Loda M, Signoretti S. p63 promotes cell survival through fatty acid synthase. PLoS One. 2009; 4(6):e5877.
39. Walker SR, Nelson EA, Zou L, Chaudhury M, Signoretti S, Richardson A, Frank DA. Reciprocal effects of STAT5 and STAT3 in breast cancer. Mol Cancer Res. 2009 Jun; 7(6):966-76.
40. Beroukhim R, Brunet JP, Di Napoli A, Mertz KD, Seeley A, Pires MM, Linhart D, Worrell RA, Moch H, Rubin MA, Sellers WR, Meyerson M, Linehan WM, Kaelin WG, Signoretti S. Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. Cancer Res. 2009 Jun 1; 69(11):4674-81.
41. Schor-Bardach R, Alsop DC, Pedrosa I, Solazzo SA, Wang X, Marquis RP, Atkins MB, Regan M, Signoretti S, Lenkinski RE, Goldberg SN. Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? Radiology. 2009 Jun; 251(3):731-42.
42. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst. 2009 Apr 1; 101(7):519-32.
43. Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM, Sukhatme VP, Seth P. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Ther. 2009 Mar; 8(3):626-35.
44. Hulick P, Zimmer M, Margulis V, Skates S, Hamel M, Dahl M. D, Michaelson D, Liebermann T, Signoretti S, Carney W, Wood C, Iliopoulos O. Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. Clin Proteom. 2009; 5:37-45.
45. Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek WK, Wang S, Ellwood-Yen K, Wu H, Sawyers CL, Signoretti S, Hahn WC, Loda M, Sellers WR. A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell. 2008 Aug 12; 14(2):146-55.
46. Sabir A, Schor-Bardach R, Wilcox CJ, Rahmanuddin S, Atkins MB, Kruskal JB, Signoretti S, Raptopoulos VD, Goldberg SN. Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. AJR Am J Roentgenol. 2008 Jul; 191(1):133-9.
47. Jia S, Liu Z, Zhang S, Liu P, Zhang L, Lee SH, Zhang J, Signoretti S, Loda M, Roberts TM, Zhao JJ. Essential roles of PI(3)K-p110beta in cell growth, metabolism and tumorigenesis. Nature. 2008 Aug 7; 454(7205):776-9.
48. Young AP, Schlisio S, Minamishima YA, Zhang Q, Li L, Grisanzio C, Signoretti S, Kaelin WG. VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400. Nat Cell Biol. 2008 Mar; 10(3):361-9.
49. Cho D, Signoretti S, Dabora S, Regan M, Seeley A, Mariotti M, Youmans A, Polivy A, Mandato L, McDermott D, Stanbridge E, Atkins M. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer. 2007 Sep; 5(6):379-85.
50. Hakimé A, Hines-Peralta A, Peddi H, Atkins MB, Sukhatme VP, Signoretti S, Regan M, Goldberg SN. Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. Radiology. 2007 Aug; 244(2):464-70.
51. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51.
52. Zhan Q, Signoretti S, Whitaker-Menezes D, Friedman TM, Korngold R, Murphy GF. Cytokeratin15-positive basal epithelial cells targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype. J Invest Dermatol. 2007 Jan; 127(1):106-15.
53. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta M, Egevad L, Ertoy-Baydar D, Farre X, Farree X, Fine SW, Iczkowski KA, Ittmann M, Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA, Shah RB, Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A, Hoque A, Lucia MS. A working group classification of focal prostate atrophy lesions. Am J Surg Pathol. 2006 Oct; 30(10):1281-91.
54. Berger R, Lin DI, Nieto M, Sicinska E, Garraway LA, Adams H, Signoretti S, Hahn WC, Loda M. Androgen-dependent regulation of Her-2/neu in prostate cancer cells. Cancer Res. 2006 Jun 1; 66(11):5723-8.
55. Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, Goldberg SN. Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology. 2006 Jul; 240(1):82-9.
56. Signoretti S, Pires MM, Lindauer M, Horner JW, Grisanzio C, Dhar S, Majumder P, McKeon F, Kantoff PW, Sellers WR, Loda M. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A. 2005 Aug 9; 102(32):11355-60.
57. Luo J, Sobkiw CL, Logsdon NM, Watt JM, Signoretti S, O'Connell F, Shin E, Shim Y, Pao L, Neel BG, Depinho RA, Loda M, Cantley LC. Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. Proc Natl Acad Sci U S A. 2005 Jul 19; 102(29):10238-43.
58. Atkins M, Regan M, McDermott D, Mier J, Stanbridge E, Youmans A, Febbo P, Upton M, Lechpammer M, Signoretti S. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res. 2005 May 15; 11(10):3714-21.
59. Ahmed M, Liu Z, Lukyanov AN, Signoretti S, Horkan C, Monsky WL, Torchilin VP, Goldberg SN. Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology. 2005 May; 235(2):469-77.
60. Zea AH, Rodriguez PC, Atkins MB, Hernandez C, Signoretti S, Zabaleta J, McDermott D, Quiceno D, Youmans A, O'Neill A, Mier J, Ochoa AC. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res. 2005 Apr 15; 65(8):3044-8.
61. Horkan C, Dalal K, Coderre JA, Kiger JL, Dupuy DE, Signoretti S, Halpern EF, Goldberg SN. Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model. Radiology. 2005 Apr; 235(1):81-8.
62. Berger R, Febbo PG, Majumder PK, Zhao JJ, Mukherjee S, Signoretti S, Campbell KT, Sellers WR, Roberts TM, Loda M, Golub TR, Hahn WC. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res. 2004 Dec 15; 64(24):8867-75.
63. Murphy M, Carlson JA, Keough MP, Claffey KP, Signoretti S, Loda M. Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin-dependent kinase inhibitor p27. J Cutan Pathol. 2004 Aug; 31(7):477-82.
64. Graner E, Tang D, Rossi S, Baron A, Migita T, Weinstein LJ, Lechpammer M, Huesken D, Zimmermann J, Signoretti S, Loda M. The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. Cancer Cell. 2004 Mar; 5(3):253-61.
65. Garraway LA, Lin D, Signoretti S, Waltregny D, Dilks J, Bhattacharya N, Loda M. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate. 2003 May 15; 55(3):206-18.
66. Lindeman N, Waltregny D, Signoretti S, Loda M. Gene transcript quantitation by real-time RT-PCR in cells selected by immunohistochemistry-laser capture microdissection. Diagn Mol Pathol. 2002 Dec; 11(4):187-92.
67. Weinstein MH, Signoretti S, Loda M. Diagnostic utility of immunohistochemical staining for p63, a sensitive marker of prostatic basal cells. Mod Pathol. 2002 Dec; 15(12):1302-8.
68. Bardeesy N, Sinha M, Hezel AF, Signoretti S, Hathaway NA, Sharpless NE, Loda M, Carrasco DR, DePinho RA. Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature. 2002 Sep 12; 419(6903):162-7.
69. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest. 2002 Sep; 110(5):633-41.
70. Gounari F, Signoretti S, Bronson R, Klein L, Sellers WR, Kum J, Siermann A, Taketo MM, von Boehmer H, Khazaie K. Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene. 2002 Jun 13; 21(26):4099-107.
71. Bardeesy N, Morgan J, Sinha M, Signoretti S, Srivastava S, Loda M, Merlino G, DePinho RA. Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol. 2002 Jan; 22(2):635-43.
72. DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers W, Loda M, Brown M. Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res. 2002 Jan 1; 62(1):89-98.
73. Signoretti S, Marmarou A, Fatouros P, Hoyle R, Beaumont A, Sawauchi S, Bullock R, Young H. Application of chemical shift imaging for measurement of NAA in head injured patients. Acta Neurochir Suppl. 2002; 81:373-5.
74. Datta MW, Macri E, Signoretti S, Renshaw AA, Loda M. Transition from in situ to invasive testicular germ cell neoplasia is associated with the loss of p21 and gain of mdm-2 expression. Mod Pathol. 2001 May; 14(5):437-42.
75. Waltregny D, Leav I, Signoretti S, Soung P, Lin D, Merk F, Adams JY, Bhattacharya N, Cirenei N, Loda M. Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. Mol Endocrinol. 2001 May; 15(5):765-82.
76. Ascoli V, Signoretti S, Onetti-Muda A, Pescarmona E, Della-Rocca C, Nardi F, Mastroianni CM, Gastaldi R, Pistilli A, Gaidano G, Carbone A, Lo-Coco F. Primary effusion lymphoma in HIV-infected patients with multicentric Castleman's disease. J Pathol. 2001 Feb; 193(2):200-9.
77. Gesbert F, Sellers WR, Signoretti S, Loda M, Griffin JD. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway. J Biol Chem. 2000 Dec 15; 275(50):39223-30.
78. Signoretti S, Montironi R, Manola J, Altimari A, Tam C, Bubley G, Balk S, Thomas G, Kaplan I, Hlatky L, Hahnfeldt P, Kantoff P, Loda M. Her-2-neu expression and progression toward androgen independence in human prostate cancer. J Natl Cancer Inst. 2000 Dec 6; 92(23):1918-25.
79. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol. 2000 Dec; 20(23):8969-82.
80. Signoretti S, Waltregny D, Dilks J, Isaac B, Lin D, Garraway L, Yang A, Montironi R, McKeon F, Loda M. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000 Dec; 157(6):1769-75.
81. Cangi MG, Cukor B, Soung P, Signoretti S, Moreira G, Ranashinge M, Cady B, Pagano M, Loda M. Role of the Cdc25A phosphatase in human breast cancer. J Clin Invest. 2000 Sep; 106(6):753-61.
82. Murphy M, Signoretti S, Kadin ME, Loda M. Detection of TCR-gamma gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. J Cutan Pathol. 2000 May; 27(5):228-34.
83. Narducci MG, Pescarmona E, Lazzeri C, Signoretti S, Lavinia AM, Remotti D, Scala E, Baroni CD, Stoppacciaro A, Croce CM, Russo G. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. Cancer Res. 2000 Apr 15; 60(8):2095-100.
84. Signoretti S, Murphy M, Puddu P, DeCoteau JF, Faraggiana T, Kadin ME, Loda M. Clonality of cutaneous B-cell infiltrates determined by microdissection and immunoglobulin gene rearrangement. Diagn Mol Pathol. 1999 Dec; 8(4):176-82.
85. Murphy M, Signoretti S, Nasser I, Sherburne B, Loda M. Detection of concurrent/recurrent non-Hodgkin's lymphoma in effusions by PCR. Hum Pathol. 1999 Nov; 30(11):1361-6.
86. Signoretti S, Annessi G, Puddu P, Faraggiana T. Melanocytic nevi of palms and soles: a histological study according to the plane of section. Am J Surg Pathol. 1999 Mar; 23(3):283-7.
87. Signoretti S, Murphy M, Cangi MG, Puddu P, Kadin ME, Loda M. Detection of clonal cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. Am J Pathol. 1999 Jan; 154(1):67-75.
88. Ascoli V, NardiF, Carnovale Scalzo C, Signoretti S, Pistilli A, Lo coco F. Absence of HHV-8 sequences in malignant mesotelioma. Mol Pathol, 1998;51:113-14.
89. Sgnoretti S, Annessi G. Are histopathological attributes of nevi and melanomas on volar skin related to skin markings? Dermatopathology: practical and conceptual. 1998;4:311-313.
90. Singh SP, Lipman J, Goldman H, Ellis FH, Aizenman L, Cangi MG, Signoretti S, Chiaur DS, Pagano M, Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 1998 Apr 15; 58(8):1730-5.
91. Cerroni L, Signoretti S, Höfler G, Annessi G, Pütz B, Lackinger E, Metze D, Giannetti A, Kerl H. Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. Am J Surg Pathol. 1997 Nov; 21(11):1307-15.
92. Annessi G, Signoretti S, Angelo C, Paradisi M, Puddu P. Neutrophilic figurate erythema of infancy. Am J Dermatopathol. 1997 Aug; 19(4):403-6.
93. Signoretti S, Annessi G, Occhiuto S, Ruatti P, Faraggiana T. Papular clear cell hyperplasia of the eccrine duct in a diabetic. Br J Dermatol. 1996 Jul; 135(1):139-43.
94. Benucci R, Annessi G, Signoretti S, Simoni R. Minimally differentiated acute myeloid leukemia revealed by specific cutaneous lesions. Brit J. Dermatol. 1996;135:119-23.
95. Muhlhauser J, Jones M, Yamada I, Cirielli C, Lemarchand P, Gloe TR, Bewig B, Signoretti S, Crystal RG, Capogrossi MC: Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. Gene Ther. 1996;3:145-53.
96. Di Tondo U, Ciardi A, Pecorella I, Signoretti S, Taccogna S, Berloco P, Cinti P, Caricato M, Iaplelli M, Alfani D, Cortesini R. Postoperative liver transplant monitoring with fine-needle aspiration biopsy. Transplant Proc. 1989;21:2311-12

Review Articles & Editorials

1. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A and Cardiff RD. Animal models of human prostate cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013;73(9):2718-2736.
2. Choueiri TK, Pomerantz MM, Signoretti S. RCC genetics: one step closer to a new classification of the disease. Lancet Oncol. 2013;14:105-7.
3. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG Jr, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, The BT, Wood CG, Zurita, AJ and King L. Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference. Cancer. 2009;115(10 Suppl):2247-51.
4. Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S. Treatment Selection for Patients With Metastatic Renal Cell Carcinoma. Cancer. 2009;115(10 Suppl):2327-33.
5. Di Napoli A and Signoretti S. Tissue Biomarkers in Renal Cell Carcinoma: Issues and Solutions. Cancer. 2009;115(10 Suppl):2290-7.
6. Signoretti S. Tissue-Based Research in the Era of ‘Personalized Medicine’: Biomarkers, Microarrays, and Beyond. Kidney Cancer Journal. 2008;235-9.
7. Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, Thomas GV, Pins MR, Libermann T, Gillespie J, Tomaszewski JE, Compton CC, Hruszkewycz A, Linehan WM, Atkins MB. Tissue-Based Research In Kidney Cancer: Current Challenges And Future Directions. Clin Cancer Res. 2008;14(12):3699-705.
8. Signoretti S, Regan M, Atkins MB. Carbonic Anhydrase IX (CAIX) as a predictive biomarker of response to kidney cancer therapy. BJU Int. 2008; 101 Suppl 4:31-5.
9. Grisanzio C and Signoretti S. p63 in prostate biology and pathology. J Cell Biochem. 2008; 103(5):1354-68.
10. Signoretti S and Loda M. Prostate stem cells: from development to cancer. Semin Cancer Biol. 2007; 17(3):219-24.
11. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13(2 Pt 2):758s-763s
12. Signoretti S and Loda M. Defining stem cells in the prostate epithelium. Cell Cycle. 2006; 5:138-41.
13. Signoretti S, Loda M. Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am J Pathol 2001;159:13-6.

Chapters In Books

1. Signoretti S, Choueiri TK, Kaelin WG. Molecular abnormalities in Kidney Cancer. In “Mendelsohn, The Molecular Basis of Cancer”. Edited by John Mendelsohn. 4th Edition. In Press.
2. Bahamon B and Signoretti S. Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC. Edited by Kimryn Rathmell, Brian Rini and Robert A. Figlin. In Press.
3. Grisanzio C and Signoretti S. Adult Prostate Epithelium Renewal, Stem Cells and Cancer. In “Stem Cells and Cancer”. Edited by Rebecca G. Bagley and Beverly A. Teicher. 2009.
4. Kamino H, Signoretti S, Weedon D. Site specific nevi. In “WHO classification of tumors: Pathology and Genetics of Skin Tumors”. Edited by LeBoit PE, Burg G, Weedon D, Sarasin A.